#169 скачать в хорошем качестве

#169

Extravesical use of BotulinumToxinA: Does it affect Urological applications? Is it time to consider a patient botulinum toxin passport? Lilis L1, Hafezi-Bakhtiari N2, Carey M2, Sharma D2, Seth J2 1. Homerton University Hospital, 2. St George's Hospital KEYWORDS: Detrusor Overactivity, Overactive Bladder, Retrospective Study Introduction: Intravesical Botulinum Toxin Type A (BoNT-A) is a commonly performed Urological procedure to treat neuropathic and non-neuropathic patients with detrusor overactivity. Botulinum toxin is also commonly used by other medical specialities to treat other pathologies such as migraine, spasticity and for cosmetic reasons. It was noted that, these patients are receiving Botulinum Toxin injections in multiple body sites, which may risk large cumulated doses. This risks toxicity or an immunological response that reduces efficacy of subsequent treatments. Aims: This study aims to investigate what percent of patients receiving intravesical BoNT-A, were also receiving extravesical-site Botulinum Toxin over a set time period, and to identify what is the total safe cumulative maximum dose that can be administered to a patient. Read the full abstract text here:   ics.org/2020/abstract/169